<HashMap><database>EGA</database><scores/><additional><omics_type>Genomics</omics_type><dataset_type>N/A</dataset_type><full_dataset_link>https://ega-archive.org/datasets/EGAD00001006585</full_dataset_link><sample_count>30</sample_count><description>EGA dataset EGAD00001006585</description><repository>EGA</repository><title>Measurable residual disease in elderly acute myeloid leukemia: results from the PETHEMA-FLUGAZA phase III clinical trial</title></additional><is_claimable>false</is_claimable><name>93451a52-efd0-40f7-a5ca-f6e94d159857 - samples</name><description>In our study, we hypothetyzed that CD34progenitors from cases with undetectable Minimal residual Disease (MRD) by flow cytometry  would contain cells with leukemic-initiating-potential that could be identified on genetic (rather than phenotypic) grounds by Whole Exome Sequencing.</description><dates><updated>2020-11-25 08:35:12</updated></dates><accession>EGAD00001006585</accession><cross_references><TAXONOMY>9606</TAXONOMY><EGA>EGAC00001001806</EGA><EGA>EGAS00001004574</EGA></cross_references></HashMap>